Your browser version is outdated. We recommend that you update your browser to the latest version.

DeNovX is ...

DeNovX Patent 9,193,664 Issues After "First Action Allowance"

Posted 11/25/2015

DeNovX's first company-owned patent issued on November 24, 2015 in a comparatively rare "first action allowance" (i.e., no objections from USPTO).  The allowance took just under 18 months, well ahead of the 29 month average pendency for this group of examiners.  The patent covers new and more efficient methods of creating crystalline materials for use in the food, pharmaceutical, medical nutrition, nutraceutical, cosmetic, agricultural, fine chemicals, and bioengineering fields.

 DeNovX scientists are actively developing new products and services that use the patented crystal formation technologies, with initial target customers in pharmaceutical R&D and specialty Contract Research Organizations (CROs) where the crystallization of small molecule Active Pharmaceutical Ingredients (APIs) is a challenging and important early step in drug development.  Contact Us if you are interested in learning more about these new technologies or the intellectual property, and know that we are interested in learning more about your crystallization needs.